Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)

Cancers 2023 February 7 [Link] Elisabetta Parisi, Donatella Arpa, Giulia Ghigi, Lucia Fabbri, Flavia Foca, Luca Tontini, Elisa Neri, Martina Pieri, Simona Cima, Marco Angelo Burgio, Maria Luisa Belli, Luca Luzzi, Antonino Romeo Abstract Malignant Pleural Mesothelioma (MPM) is a rare malignancy with an overall poor prognosis. The standard therapeutic strategy in early-stage disease is…

Read More

Importance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma

The Thoracic and Cardiovascular Surgeon 2023 February 3 [Link] İlteriş Türk, Gokturk Findik, Mehmet Çetin, Pinar Bicakcioglu, Selim Şakir Erkmen Gülhan, Koray Aydoğdu, Ülkü Yılmaz, Funda Demirağ Abstract Background: Complexities in TNM staging in epithelioid malignant pleural mesothelioma (MPM) may lead to errors in treatment selection, leading to major surgical interventions in patients with low…

Read More

Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports

Case Reports in Oncology 2022 November 8 [Link] Dominik Neff, Barbara-Christina Padberg Sgier, Hannah Dietze, Joachim Müller, Martin Früh Abstract Malignant peritoneal mesothelioma is a rare disease. Patients mainly present with abdominal distension, pain, nausea, and weight loss with or without an exposure history of asbestos. Diagnosis may be difficult from a clinical and histopathologic…

Read More

Carbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma

American Journal of Cancer Research 2022 December 15 [Link] Sei Sai, Taiju Yamada, Keiko Ito, Nobuyuki Kanematsu, Masao Suzuki, Mitsuhiro Hayashi, Masashi Koto Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer. This study investigated the growth-inhibitory effects of the combination of carbon ion beam irradiation (IR) and cisplatin (CDDP) on MPM xenografts. Carbon-ion…

Read More

Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach

Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…

Read More

Multifactorial Evaluation following Cytoreductive Surgery for Malignant Pleural Mesothelioma in Patients with High Symptom-Burden

Journal of Clinical Medicine 2022 October 29 [Link] Riccardo Tajè, Roberto Fiorito, Alexandro Patirelis, Valentina Marziali, Vincenzo Ambrogi Abstract Mesothelioma has a scant prognosis and a great impact on symptoms and the quality of life. Pleurectomy/decortication and extrapleural pneumonectomy are the two cytoreductive surgical strategies, with different invasiveness, but achieving similar oncological results. Hereafter, the…

Read More

Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy

International Journal of Radiation Oncology, Biology, Physics 2022 October 3 [Link] Michela Cangemi, Marcella Montico, Marco Trovo, Emilio Minatel, Emanuela Di Gregorio, Giuseppe Corona, Fabiana Giordari, Elisa Comaro, Francesca Colizzi, Lorena Baboçi, Agostino Steffan, Alberto Revelant, Elena Muraro Abstract Purpose: The present study aimed at evaluating the baseline immune profile and the immunomodulating effects of…

Read More

Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration

Scientific Reports 2022 October 4 [Link] Kui Fan, Chuan-Long Zhang, Bo-Hui Zhang, Meng-Qi Gao, Yun-Chuan Sun Abstract Mesothelioma lies one of the most malignant tumors, in which the identification of the corresponding biomarkers is extremely critical. This study aims to investigate the prognostic value of enhancer homolog 2 (EZH2) mRNA expression in mesothelioma patients accompanied…

Read More

BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation

BMC Cancer 2022 September 15 [Link] Nguyen Truong Duc Hoang, Ghmkin Hassan, Tomoya Suehiro, Yuichi Mine, Tohru Matsuki, Makiko Fujii Abstract Background: Malignant mesothelioma (MM) is an aggressive mesothelial cell cancer type linked mainly to asbestos inhalation. MM characterizes by rapid progression and resistance to standard therapeutic modalities such as surgery, chemotherapy, and radiotherapy. Our…

Read More